Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04677712 · ClinicalTrials.gov registry record · Phase 4
Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT04677712: Completed Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT04677712 is a Phase 4 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 48 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04677712, a Phase 4 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study will investigate treatments that may mitigate bruising after QWO™ (Collagenase clostridium histolyticum \[CCH\]-aaes) treatment of cellulite in the buttocks.
Primary Outcome
Participants were assessed by the investigator using the Investigator Assessment of Bruising Severity Scale. The Investigator Assessment of Bruising Severity Scale is a 5-point photonumeric scale ranging from 0 to 4, with "0" indicating no bruising or almost none, and "4" indicating very severe bruising. Higher scores indicated worse outcome.
Interventions
- DRUG CCH-aaes
- OTHER Compression
- OTHER Cold Packs
- DRUG Arnica Gel
- DRUG INhance®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 4 |
What the finished NCT04677712 record still lists
NCT04677712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 5 interventions - of which CCH-aaes is the first listed.
NCT04677712 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04677712 about?
NCT04677712 is a clinical study titled "Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite". This study will investigate treatments that may mitigate bruising after QWO™ (Collagenase clostridium histolyticum \[CCH\]-aaes) treatment of cellulite in the buttocks.
What is the current status of trial NCT04677712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2020-12-28. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT04677712?
The interventions under investigation include: CCH-aaes (DRUG), Compression (OTHER), Cold Packs (OTHER), Arnica Gel (DRUG), INhance® (DRUG).
Who is sponsoring clinical trial NCT04677712?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04677712's enrollment target sits among peer trials
48 1331st of 2000 higher than 653 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI